Sunday, April 05, 2020 5:55:01 PM
The following are the CONTINGENT VALUE RIGHTS Agreements and links to SEC Filings for;
Ligand pharmaceuticals Inc. (LGND) Nasdaq - FORM 8-K January 27, 2010
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/d8k.htm
There is an individual SEC filing for each CRV below as well.
LGNDZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex101.htm
Roche Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010
Roche CVR. The Roche CVR Agreement entitles each holder of a Roche CVR to receive a pro rata portion of 65% of any milestone payments or 68% of any royalties paid by Roche under Metabasis’ partnered drug development program with Roche in hepatitis C, or 65% of the net proceeds of any sale of those program rights.
=================
The following are CRV's from the Acquisition of Metabasis Therapeutics, Inc. on January 28, 2010
News Release on the Merger Completion of ligand and Metabasis Therapeutics, Inc.,: https://www.businesswire.com/news/home/20100128005321/en/Ligand-Completes-Acquisition-Metabasis
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/0001193125-10-015242-index.htm
LGNZZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex102.htm
TR Beta Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010
TR Beta CVR. The TR Beta CVR Agreement entitles each holder of a TR Beta CVR to receive a pro rata portion of a percentage of the net proceeds of any license or sale of Metabasis’ Thyroid Receptor Beta program in hyperlipidemia: 50% of such net proceeds if the licensing/sale transaction occurs by the sixth anniversary of the Merger; 40% if in the seventh year after the Merger; 30% if in the eighth year after the Merger; or 20% if in the ninth or tenth year after the Merger.
LGNXZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex103.htm
Glucagon Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010
Glucagon CVR. The Glucagon CVR Agreement entitles each holder of a Glucagon CVR to receive a pro rata portion of a percentage of the net proceeds of any license or sale of Metabasis’ glucagon receptor antagonist program in diabetes: 50% of such net proceeds if the licensing/sale transaction occurs by the sixth anniversary of the Merger; 40% if in the seventh year after the Merger; 30% if in the eighth year after the Merger; or 20% if in the ninth or tenth year after the Merger.
https://www.businesswire.com/news/home/20100128005321/en/Ligand-Completes-Acquisition-Metabasis
LGNYZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex104.htm
General Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010
General CVR. The General CVR Agreement entitles each holder of a General CVR to receive a pro rata portion of cash payments equal to the shortfall, if any, from defined spending thresholds of Ligand’s funding of further research and development of drug development programs acquired from Metabasis. The basic threshold is $8 million of funding within the first 42 months after the Merger. A secondary threshold (which shall be waived in certain circumstances) is $7 million of funding within the first 30 months after the Merger.
Ligand pharmaceuticals Inc. (LGND) Nasdaq - FORM 8-K January 27, 2010
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/d8k.htm
There is an individual SEC filing for each CRV below as well.
LGNDZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex101.htm
Roche Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010
Roche CVR. The Roche CVR Agreement entitles each holder of a Roche CVR to receive a pro rata portion of 65% of any milestone payments or 68% of any royalties paid by Roche under Metabasis’ partnered drug development program with Roche in hepatitis C, or 65% of the net proceeds of any sale of those program rights.
=================
The following are CRV's from the Acquisition of Metabasis Therapeutics, Inc. on January 28, 2010
News Release on the Merger Completion of ligand and Metabasis Therapeutics, Inc.,: https://www.businesswire.com/news/home/20100128005321/en/Ligand-Completes-Acquisition-Metabasis
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/0001193125-10-015242-index.htm
LGNZZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex102.htm
TR Beta Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010
TR Beta CVR. The TR Beta CVR Agreement entitles each holder of a TR Beta CVR to receive a pro rata portion of a percentage of the net proceeds of any license or sale of Metabasis’ Thyroid Receptor Beta program in hyperlipidemia: 50% of such net proceeds if the licensing/sale transaction occurs by the sixth anniversary of the Merger; 40% if in the seventh year after the Merger; 30% if in the eighth year after the Merger; or 20% if in the ninth or tenth year after the Merger.
LGNXZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex103.htm
Glucagon Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010
Glucagon CVR. The Glucagon CVR Agreement entitles each holder of a Glucagon CVR to receive a pro rata portion of a percentage of the net proceeds of any license or sale of Metabasis’ glucagon receptor antagonist program in diabetes: 50% of such net proceeds if the licensing/sale transaction occurs by the sixth anniversary of the Merger; 40% if in the seventh year after the Merger; 30% if in the eighth year after the Merger; or 20% if in the ninth or tenth year after the Merger.
https://www.businesswire.com/news/home/20100128005321/en/Ligand-Completes-Acquisition-Metabasis
LGNYZ
=====
https://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex104.htm
General Contingent Value Rights Agreement, by and among Ligand Pharmaceuticals Incorporated, Metabasis Therapeutics, Inc., David F. Hale, as Stockholders’ Representative, and Mellon Investor Services LLC as Rights Agent, dated January 27, 2010
General CVR. The General CVR Agreement entitles each holder of a General CVR to receive a pro rata portion of cash payments equal to the shortfall, if any, from defined spending thresholds of Ligand’s funding of further research and development of drug development programs acquired from Metabasis. The basic threshold is $8 million of funding within the first 42 months after the Merger. A secondary threshold (which shall be waived in certain circumstances) is $7 million of funding within the first 30 months after the Merger.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.